Sean Maduck - 10 Nov 2022 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
10 Nov 2022
Net transactions value
-$557,000
Form type
4
Filing time
15 Nov 2022, 15:45:15 UTC
Previous filing
04 Oct 2022
Next filing
05 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $82,250 +25,000 +44% $3.29* 81,462 10 Nov 2022 Direct F2
transaction CORT Common Stock Sale $639,250 -25,000 -31% $25.57 56,462 10 Nov 2022 Direct F1, F2, F3
holding CORT Common Stock 10,000 10 Nov 2022 See Footnote F4
holding CORT Common Stock 10,000 10 Nov 2022 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -25,000 -43% $0.000000 32,602 10 Nov 2022 Common Stock 25,000 $3.29 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
F2 Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.55 to $25.65. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F4 Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F5 Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
F6 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.